{"protocolSection": {"identificationModule": {"nctId": "NCT01360021", "orgStudyIdInfo": {"id": "D589OC00003"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day", "officialTitle": "A 12-week, Double-blind, Randomized, Multi-centre, Parallel-group Study Evaluating the Efficacy Safety, and Patient Use (User Study) of Symbicort\u00ae (Budesonide/Formoterol) Breath Actuated Metered Dose Inhaler (BA MDI) 2x160/4.5 \u03bcg Twice Daily Compared With Symbicort (Budesonide/Formoterol) AC (Actuation Counter) pMDI\u00ae 2x160/4.5 \u03bcg Twice Daily and Budesonide AC pMDI 2x160 \u03bcg Twice Daily in Adult and Adolescent Asthmatics", "acronym": "BAI"}, "statusModule": {"statusVerifiedDate": "2014-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-11"}, "primaryCompletionDateStruct": {"date": "2012-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-05-19", "studyFirstSubmitQcDate": "2011-05-24", "studyFirstPostDateStruct": {"date": "2011-05-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-07-19", "resultsFirstSubmitQcDate": "2014-01-27", "resultsFirstPostDateStruct": {"date": "2014-03-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-01-27", "lastUpdatePostDateStruct": {"date": "2014-03-11", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This is a comparison of the efficacy of the Symbicort breath actuated dose inhaler to the Symbicort pressured meter dose inhaler after 12 weeks of a twice a day dose."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 214, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1 Symbicort/inhaler", "type": "ACTIVE_COMPARATOR", "description": "Symbicort BA MDI 2x160/4.5 \u03bcg twice daily", "interventionNames": ["Drug: Symbicort"]}, {"label": "Symbicort/inhaler", "type": "ACTIVE_COMPARATOR", "description": "Symbicort AC pDMI 2x160/4.5 \u03bcg twice daily", "interventionNames": ["Drug: Symbicort"]}, {"label": "Budesonide/inhaler", "type": "ACTIVE_COMPARATOR", "description": "Budesonide AC pMDI 2x160 \u03bcg twice daily", "interventionNames": ["Drug: Budesonide"]}], "interventions": [{"type": "DRUG", "name": "Symbicort", "description": "Breath actuated metered dose inhaler", "armGroupLabels": ["1 Symbicort/inhaler"]}, {"type": "DRUG", "name": "Symbicort", "description": "Actuation counter pressured metered dose inhaler", "armGroupLabels": ["Symbicort/inhaler"]}, {"type": "DRUG", "name": "Budesonide", "description": "Actuation counter pressured metered dose inhaler", "armGroupLabels": ["Budesonide/inhaler"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Forced Expiratory Volume in 1 Second (FEV1) - Post Dose", "description": "Descriptive statistics for post-dose FEV1 (L) by visit; Baseline defined as the last pre-dose value prior to 1st dose of randomized therapy. Trt Avg = Mean of all available valid values after randomization.", "timeFrame": "60 minutes post-dose in clinic visits at baseline, and week 0, 3, 7, 12 and Trt Avg"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) - Pre Dose", "description": "Descriptive statistics for predose FEV1(L) by visit; Baseline defined as the last pre-dose value prior to 1st dose of randomized therapy. Trt Avg = Mean of all available valid values after randomization.", "timeFrame": "Pre AM dose in clinic visits at baseline, and week 3, 7, 12 and Trt Avg"}], "secondaryOutcomes": [{"measure": "Peak Expiratory Flow", "timeFrame": "Recorded morning upon rising and evening before sleep for 14 weeks"}, {"measure": "Asthma Symptoms Score (Total)", "description": "The total score is calculated as sum of the morning and evening scores of each day and the treatment period mean score is defined as the mean of all total score recorded during the 12-week treatment period. Trt Avg=Mean total score of double-blind period values.(day/night score ranges from 0 to 3; 0=no asthma symptoms; 3= unable to do normal activities (or to sleep) due to asthma). Higher score represents worse outcome.", "timeFrame": "Recorded between 6:00 - 11:00 AM from previous 12 hours and 6:00 -11:00 PM from previous 12 hours for 14 weeks"}, {"measure": "Night-time Awakenings Due to Asthma Symptoms(% Awakening-free Nights)", "description": "The percentage of days with no awakenings due to asthma. Baseline= Mean % awakening-free nights during run-in period ; Trt Avg=Mean % awakening-free nights during double-blind period.", "timeFrame": "Recorded 6:00 - 11:00 AM for 14 weeks"}, {"measure": "Use of Rescue Medication Day and Night (Total Daily Rescue Medication Use)", "description": "Total daily rescue medication use is calculated as the sum of morning and evening use each day and averaged over the 12 weeks treatment periods to calculate the treatment period mean. Baseline= Mean rescue medication used during run-in period ; Trt Avg=Mean rescue medication used during double-blind period.", "timeFrame": "Recorded between 6:00 - 11:00 AM from previous 12 hours and 6:00 -11:00 PM from previous 12 hours for 14 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female 12 years and above\n* Clinical diagnosis of asthma according to the American Thoracic Society definition at least 6 months\n* Pre-bronchodilator FEV1 \u2265 45% and \u2264 85% of predicted normal\n* Patients with reversible airway obstruction\n* Documented daily use of inhaled corticosteroids for \u2265 3 months\n\nExclusion Criteria:\n\n* History of life-threatening asthma, defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures during the 2 years prior to Visit 2\n* Hospitalized during previous 6 months for asthma\n* Required emergency treatment more than once during previous 6 months for an asthma-related condition\n* Intake of oral, rectal or parenteral glucocorticosteroid within 30 days of enrolment\n* Respiratory infection affecting the asthma within 30 days", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Goran Eckerwall, MD", "affiliation": "AstraZeneca R&D, M\u00f6lndal", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Huntington Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Research Site", "city": "Long Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "Research Site", "city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "Orange", "state": "California", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "Research Site", "city": "Rancho Mirage", "state": "California", "country": "United States", "geoPoint": {"lat": 33.73974, "lon": -116.41279}}, {"facility": "Research Site", "city": "Riverside", "state": "California", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Research Site", "city": "Sacramento", "state": "California", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "Research Site", "city": "San Diego", "state": "California", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Research Site", "city": "San Jose", "state": "California", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "Research Site", "city": "Tallahassee", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.43826, "lon": -84.28073}}, {"facility": "Research Site", "city": "Savannah", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Research Site", "city": "River Forest", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 41.89781, "lon": -87.81395}}, {"facility": "Research Site", "city": "Louisville", "state": "Kentucky", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "Research Site", "city": "Metairie", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 29.98409, "lon": -90.15285}}, {"facility": "Research Site", "city": "Bangor", "state": "Maine", "country": "United States", "geoPoint": {"lat": 44.80118, "lon": -68.77781}}, {"facility": "Research Site", "city": "Wheaton", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.03983, "lon": -77.05526}}, {"facility": "Research Site", "city": "North Dartmouth", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "Research Site", "city": "Columbia", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.95171, "lon": -92.33407}}, {"facility": "Research Site", "city": "Rolla", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 37.95143, "lon": -91.77127}}, {"facility": "Research Site", "city": "Skillman", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 40.42011, "lon": -74.7146}}, {"facility": "Research Site", "city": "North Syracuse", "state": "New York", "country": "United States", "geoPoint": {"lat": 43.13479, "lon": -76.12992}}, {"facility": "Research Site", "city": "Rochester", "state": "New York", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Collegeville", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.18566, "lon": -75.45157}}, {"facility": "Research Site", "city": "Lincoln", "state": "Rhode Island", "country": "United States", "geoPoint": {"lat": 41.92111, "lon": -71.435}}, {"facility": "Research Site", "city": "Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Research Site", "city": "Spartanburg", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Research Site", "city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Research Site", "city": "Tacoma", "state": "Washington", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}, {"facility": "Research Site", "city": "Greenfield", "state": "Wisconsin", "country": "United States", "geoPoint": {"lat": 42.9614, "lon": -88.01259}}, {"facility": "Research Site", "city": "Madison", "state": "Wisconsin", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "Research Site", "city": "Ruse", "country": "Bulgaria", "geoPoint": {"lat": 43.85639, "lon": 25.97083}}, {"facility": "Research Site", "city": "Sevlievo", "country": "Bulgaria", "geoPoint": {"lat": 43.02583, "lon": 25.11361}}, {"facility": "Research Site", "city": "Sofia", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Research Site", "city": "Varna", "country": "Bulgaria", "geoPoint": {"lat": 43.21667, "lon": 27.91667}}, {"facility": "Research Site", "city": "Balassagyarmat", "country": "Hungary", "geoPoint": {"lat": 48.07296, "lon": 19.29614}}, {"facility": "Research Site", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Research Site", "city": "Salgotarjan", "country": "Hungary", "geoPoint": {"lat": 48.09872, "lon": 19.80303}}, {"facility": "Research Site", "city": "Szazhalombatta", "country": "Hungary", "geoPoint": {"lat": 47.32579, "lon": 18.92141}}, {"facility": "Research Site", "city": "Ekaterinburg", "state": "Russia", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}, {"facility": "Research Site", "city": "Moscow", "state": "Russia", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}]}, "referencesModule": {"references": [{"pmid": "25596138", "type": "DERIVED", "citation": "Murphy KR, Dhand R, Trudo F, Uryniak T, Aggarwal A, Eckerwall G. Therapeutic equivalence of budesonide/formoterol delivered via breath-actuated inhaler vs pMDI. Respir Med. 2015 Feb;109(2):170-9. doi: 10.1016/j.rmed.2014.12.009. Epub 2015 Jan 3."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Symbicort BA MDI", "description": "Symbicort BA MDI 2x160/4.5 \u03bcg twice daily"}, {"id": "FG001", "title": "Symbicort pMDI", "description": "Symbicort AC pDMI 2x160/4.5 \u03bcg twice daily"}, {"id": "FG002", "title": "Budesonide", "description": "Budesonide AC pMDI 2x160 \u03bcg twice daily"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Patients randomized", "numSubjects": "71"}, {"groupId": "FG001", "comment": "Patients randomized", "numSubjects": "71"}, {"groupId": "FG002", "comment": "Patients randomized", "numSubjects": "72"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Patients who completed study", "numSubjects": "63"}, {"groupId": "FG001", "comment": "Patients who completed study", "numSubjects": "67"}, {"groupId": "FG002", "comment": "Patients who completed study", "numSubjects": "65"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "7"}]}], "dropWithdraws": [{"type": "Eligibility criteria + other", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All Randomized patients", "groups": [{"id": "BG000", "title": "Symbicort BA MDI", "description": "Symbicort BA MDI 2x160/4.5 \u03bcg twice daily"}, {"id": "BG001", "title": "Symbicort pMDI", "description": "Symbicort AC pDMI 2x160/4.5 \u03bcg twice daily"}, {"id": "BG002", "title": "Budesonide", "description": "Budesonide AC pMDI 2x160 \u03bcg twice daily"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "71"}, {"groupId": "BG001", "value": "71"}, {"groupId": "BG002", "value": "72"}, {"groupId": "BG003", "value": "214"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "42.83", "spread": "16.156"}, {"groupId": "BG001", "value": "42.62", "spread": "16.873"}, {"groupId": "BG002", "value": "42.72", "spread": "14.424"}, {"groupId": "BG003", "value": "42.72", "spread": "15.770"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "12 - <18 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "7"}, {"groupId": "BG003", "value": "21"}]}]}, {"title": "18 - <65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "60"}, {"groupId": "BG001", "value": "56"}, {"groupId": "BG002", "value": "62"}, {"groupId": "BG003", "value": "178"}]}]}, {"title": "65 - <75 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "10"}]}]}, {"title": ">= 75 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "35"}, {"groupId": "BG003", "value": "119"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "37"}, {"groupId": "BG003", "value": "95"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "6"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "27"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "57"}, {"groupId": "BG001", "value": "63"}, {"groupId": "BG002", "value": "57"}, {"groupId": "BG003", "value": "177"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "3"}]}]}]}, {"title": "Years since asthma diagnosis", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "24.26", "spread": "14.891"}, {"groupId": "BG001", "value": "24.12", "spread": "15.128"}, {"groupId": "BG002", "value": "24.38", "spread": "15.183"}, {"groupId": "BG003", "value": "24.25", "spread": "14.998"}]}]}]}, {"title": "% Predicted FEV1 (Visit 2)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "67.27", "spread": "10.048"}, {"groupId": "BG001", "value": "65.02", "spread": "11.135"}, {"groupId": "BG002", "value": "68.49", "spread": "9.924"}, {"groupId": "BG003", "value": "66.93", "spread": "10.434"}]}]}]}, {"title": "% Reversibility in FEV1 (Visit 2)", "description": "Reversibility is defined as a change of \u226512% in FEV1 from pre-bronchodilator values (for patients \u226512 and \\<18 years of age), and for patients \u226518 years of age, a change of \u226512% and 200 mL in FEV1 from pre-bronchodilator values. Percent reversibility of FEV1 was calculated as follows: (Post-bronchodilator FEV1 - pre-bronchodilator FEV1)/pre-bronchodilator FEV1 x 100.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "23.93", "spread": "15.728"}, {"groupId": "BG001", "value": "28.04", "spread": "14.712"}, {"groupId": "BG002", "value": "23.64", "spread": "12.692"}, {"groupId": "BG003", "value": "25.20", "spread": "14.491"}]}]}]}, {"title": "% Reversibility in FEV1 (Visit 3)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "26.43", "spread": "16.662"}, {"groupId": "BG001", "value": "28.22", "spread": "16.118"}, {"groupId": "BG002", "value": "24.88", "spread": "14.235"}, {"groupId": "BG003", "value": "26.51", "spread": "15.692"}]}]}]}, {"title": "Baseline % Predicted FEV1 (Visit 4)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "67.78", "spread": "11.059"}, {"groupId": "BG001", "value": "67.31", "spread": "10.683"}, {"groupId": "BG002", "value": "68.27", "spread": "11.078"}, {"groupId": "BG003", "value": "67.79", "spread": "10.898"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) - Post Dose", "description": "Descriptive statistics for post-dose FEV1 (L) by visit; Baseline defined as the last pre-dose value prior to 1st dose of randomized therapy. Trt Avg = Mean of all available valid values after randomization.", "populationDescription": "Full analysis set: It consist of all randomized patients who received at least one dose of study medication and contributed sufficient data for at least one efficacy endpoint (Primary variable).", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Liter", "timeFrame": "60 minutes post-dose in clinic visits at baseline, and week 0, 3, 7, 12 and Trt Avg", "groups": [{"id": "OG000", "title": "Symbicort BA MDI", "description": "Symbicort BA MDI 2x160/4.5 \u03bcg twice daily"}, {"id": "OG001", "title": "Symbicort pMDI", "description": "Symbicort AC pDMI 2x160/4.5 \u03bcg twice daily"}, {"id": "OG002", "title": "Budesonide", "description": "Budesonide AC pMDI 2x160 \u03bcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "71"}, {"groupId": "OG002", "value": "71"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.09", "spread": "31.46"}, {"groupId": "OG001", "value": "1.97", "spread": "27.16"}, {"groupId": "OG002", "value": "2.12", "spread": "26.34"}]}]}, {"title": "Week 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.49", "spread": "32.14"}, {"groupId": "OG001", "value": "2.35", "spread": "25.97"}, {"groupId": "OG002", "value": "2.28", "spread": "27.18"}]}]}, {"title": "Week 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.52", "spread": "31.98"}, {"groupId": "OG001", "value": "2.34", "spread": "26.31"}, {"groupId": "OG002", "value": "2.30", "spread": "30.22"}]}]}, {"title": "Week 7", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.59", "spread": "32.17"}, {"groupId": "OG001", "value": "2.35", "spread": "27.22"}, {"groupId": "OG002", "value": "2.33", "spread": "29.29"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.52", "spread": "30.71"}, {"groupId": "OG001", "value": "2.39", "spread": "27.31"}, {"groupId": "OG002", "value": "2.30", "spread": "28.27"}]}]}, {"title": "Treatment Average", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.53", "spread": "30.57"}, {"groupId": "OG001", "value": "2.37", "spread": "26.33"}, {"groupId": "OG002", "value": "2.30", "spread": "28.36"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "groupDescription": "The comparison of Symbicort AC pMDI 2x160/4.5 \u00b5g bid with budesonide AC pMDI 2x160 \u00b5g bid for post dose FEV1", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model on the log transformed outcome variable with treatment and country as factor, and log transformed baseline FEV1 (pre-dose) as covariate.", "paramType": "Estimated Geometic Mean Ratio", "paramValue": "1.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.06", "ciUpperLimit": "1.14", "estimateComment": "Symbicort AC pMDI 2x160/4.5 \u00b5g bid vs Budesonide AC pMDI 2x160 \u00b5g bid"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "The comparisons of Symbicort BA MDI 2x160/4.5 \u00b5g bid with Symbicort AC pMDI 2x160/4.5 \u00b5g bid for post dose FEV1.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Assuming a standard deviation of 0.2 (for pre dose FEV1) on the log-scale and 60 patients/arm, the width of the confidence interval will extend 0.072 from the point estimate on the log-scale. The lower and upper limits of the CI for the ratio of effects will thus be obtained by multiplying the estimated ratio by 0.931 and 1.075, respectively.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model on the log transformed outcome variable with treatment and country as factor, and log transformed baseline FEV1 (pre-dose) as covariate.", "paramType": "Estimated Geometric Mean Ratio", "paramValue": "1.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.97", "ciUpperLimit": "1.05", "estimateComment": "The comparisons was used to assess therapeutic equivalence of Symbicort AC pMDI and Symbicort BA MDI. Assay sensitivity was demonstrated before proceeding to assess therapeutic equivalence of the 2 Symbicort products."}]}, {"type": "PRIMARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) - Pre Dose", "description": "Descriptive statistics for predose FEV1(L) by visit; Baseline defined as the last pre-dose value prior to 1st dose of randomized therapy. Trt Avg = Mean of all available valid values after randomization.", "populationDescription": "Full analysis set: It consist of all randomized patients who received at least one dose of study medication and contributed sufficient data for at least one efficacy endpoint (Primary variable).", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Liters", "timeFrame": "Pre AM dose in clinic visits at baseline, and week 3, 7, 12 and Trt Avg", "groups": [{"id": "OG000", "title": "Symbicort BA MDI", "description": "Symbicort BA MDI 2x160/4.5 \u03bcg twice daily"}, {"id": "OG001", "title": "Symbicort pMDI", "description": "Symbicort AC pDMI 2x160/4.5 \u03bcg twice daily"}, {"id": "OG002", "title": "Budesonide", "description": "Budesonide AC pMDI 2x160 \u03bcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "71"}, {"groupId": "OG002", "value": "71"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.09", "spread": "31.46"}, {"groupId": "OG001", "value": "1.97", "spread": "27.16"}, {"groupId": "OG002", "value": "2.12", "spread": "26.34"}]}]}, {"title": "Week 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.32", "spread": "32.79"}, {"groupId": "OG001", "value": "2.12", "spread": "28.29"}, {"groupId": "OG002", "value": "2.22", "spread": "31.21"}]}]}, {"title": "Week 7", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.40", "spread": "32.86"}, {"groupId": "OG001", "value": "2.11", "spread": "29.96"}, {"groupId": "OG002", "value": "2.25", "spread": "29.01"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.34", "spread": "30.84"}, {"groupId": "OG001", "value": "2.17", "spread": "31.29"}, {"groupId": "OG002", "value": "2.23", "spread": "30.15"}]}]}, {"title": "Average of treatment period", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.34", "spread": "30.15"}, {"groupId": "OG001", "value": "2.15", "spread": "29.15"}, {"groupId": "OG002", "value": "2.23", "spread": "29.36"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The comparisons of Symbicort BA MDI 2x160/4.5 \u00b5g bid with Symbicort AC pMDI 2x160/4.5 \u00b5g bid, for pre-dose FEV1.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Assuming a standard deviation of 0.2 (for pre dose FEV1) on the log-scale and 60 patients/arm, the width of the confidence interval will extend 0.072 from the point estimate on the log-scale. The lower and upper limits of the CI for the ratio of effects will thus be obtained by multiplying the estimated ratio by 0.931 and 1.075, respectively.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model on the log transformed outcome variable with treatment and country as factor, and log transformed baseline FEV1 (pre-dose) as covariate.", "paramType": "Estimated Geometric Mean Ratio", "paramValue": "1.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.99", "ciUpperLimit": "1.08", "estimateComment": "The comparisons was used to assess therapeutic equivalence of Symbicort AC pMDI and Symbicort BA MDI. Assay sensitivity was demonstrated before proceeding to assess therapeutic equivalence of the 2 Symbicort products."}]}, {"type": "SECONDARY", "title": "Peak Expiratory Flow", "populationDescription": "Full analysis set: It consist of all randomized patients who received at least one dose of study medication and contributed sufficient data for at least one efficacy endpoint (Primary variable).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/Min", "timeFrame": "Recorded morning upon rising and evening before sleep for 14 weeks", "groups": [{"id": "OG000", "title": "Symbicort BA MDI", "description": "Symbicort BA MDI 2x160/4.5 \u03bcg twice daily"}, {"id": "OG001", "title": "Symbicort pMDI", "description": "Symbicort AC pDMI 2x160/4.5 \u03bcg twice daily"}, {"id": "OG002", "title": "Budesonide", "description": "Budesonide AC pMDI 2x160 \u03bcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "71"}, {"groupId": "OG002", "value": "71"}]}], "classes": [{"title": "Morning Peak expiratory flow (Baseline)", "categories": [{"measurements": [{"groupId": "OG000", "value": "357.95", "spread": "100.59"}, {"groupId": "OG001", "value": "335.70", "spread": "102.99"}, {"groupId": "OG002", "value": "360.46", "spread": "103.09"}]}]}, {"title": "Evening Peak expiratory flow (Baseline)", "categories": [{"measurements": [{"groupId": "OG000", "value": "364.61", "spread": "103.62"}, {"groupId": "OG001", "value": "347.86", "spread": "110.80"}, {"groupId": "OG002", "value": "367.64", "spread": "102.73"}]}]}, {"title": "Evening Peak expiratory flow (Treatment Average)", "categories": [{"measurements": [{"groupId": "OG000", "value": "379.96", "spread": "104.72"}, {"groupId": "OG001", "value": "362.99", "spread": "112.63"}, {"groupId": "OG002", "value": "348.94", "spread": "97.94"}]}]}, {"title": "Morning Peak expiratory flow (Treatment Average)", "categories": [{"measurements": [{"groupId": "OG000", "value": "376.28", "spread": "106.76"}, {"groupId": "OG001", "value": "353.69", "spread": "108.72"}, {"groupId": "OG002", "value": "343.59", "spread": "98.12"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Morning peak expiratory flow (mPEF): Comparing mean changes from baseline to the average of the double-blind treatment period between Symbicort BA MDI 2x160/4.5 \u03bcg bid and Symbicort AC pMDI 2x160/4.5 \u00b5g bid", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "No adjustment were be made for multiplicity for these supportive variables and nominal p-values were reported.", "pValue": "0.825", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model includes treatment and country as a factor and baseline value as covariate.", "paramType": "Mean Difference (Net)", "paramValue": "1.49", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.81", "ciUpperLimit": "14.80", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.75", "estimateComment": "Secondary efficacy variables were analyzed as continuous data, comparing mean changes from baseline to the average of the double-blind treatment period between treatments. No adjustment were made for multiplicity and nominal p-values were reported."}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Morning peak expiratory flow (mPEF): Comparing mean changes from baseline to the average of the double-blind treatment period between Symbicort AC pMDI 2x160/4.5 \u00b5g bid minus Budesonide AC pMDI 2x160 \u00b5g bid", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model includes treatment and country as a factor and baseline value as covariate.", "paramType": "Mean Difference (Net)", "paramValue": "33.52", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "20.11", "ciUpperLimit": "46.93", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.80", "estimateComment": "Secondary efficacy variables were analyzed as continuous data, comparing mean changes from baseline to the average of the double-blind treatment period between treatments. No adjustment were made for multiplicity and nominal p-values were reported."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Evening peak expiratory flow (ePEF): Comparing mean changes from baseline to the average of the double-blind treatment period between Symbicort BA MDI 2x160/4.5 \u03bcg bid and Symbicort AC pMDI 2x160/4.5 \u00b5g bid.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "No adjustment were made for multiplicity for these supportive variables and nominal p-values were reported.", "pValue": "0.810", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model includes treatment and country as a factor and baseline value as covariate.", "paramType": "Mean Difference (Net)", "paramValue": "1.48", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.66", "ciUpperLimit": "13.61", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.15", "estimateComment": "Secondary efficacy variables were analyzed as continuous data, comparing mean changes from baseline to the average of the double-blind treatment period between treatments. No adjustment were made for multiplicity and nominal p-values were reported."}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Evening peak expiratory flow (ePEF): Comparing mean changes from baseline to the average of the double-blind treatment period between Symbicort AC pMDI 2x160/4.5 \u00b5g bid and Budesonide AC pMDI 2x160 \u00b5g bid.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model includes treatment and country as a factor and baseline value as covariate.", "paramType": "Mean Difference (Net)", "paramValue": "32.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "20.01", "ciUpperLimit": "44.49", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.21", "estimateComment": "Secondary efficacy variables were analyzed as continuous data, comparing mean changes from baseline to the average of the double-blind treatment period between treatments. No adjustment were made for multiplicity and nominal p-values were reported."}]}, {"type": "SECONDARY", "title": "Asthma Symptoms Score (Total)", "description": "The total score is calculated as sum of the morning and evening scores of each day and the treatment period mean score is defined as the mean of all total score recorded during the 12-week treatment period. Trt Avg=Mean total score of double-blind period values.(day/night score ranges from 0 to 3; 0=no asthma symptoms; 3= unable to do normal activities (or to sleep) due to asthma). Higher score represents worse outcome.", "populationDescription": "Full analysis set: It consist of all randomized patients who received at least one dose of study medication and contributed sufficient data for at least one efficacy endpoint (Primary variable).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Asthma score on a scale of 0 to 3", "timeFrame": "Recorded between 6:00 - 11:00 AM from previous 12 hours and 6:00 -11:00 PM from previous 12 hours for 14 weeks", "groups": [{"id": "OG000", "title": "Symbicort BA MDI", "description": "Symbicort BA MDI 2x160/4.5 \u03bcg twice daily"}, {"id": "OG001", "title": "Symbicort pMDI", "description": "Symbicort AC pDMI 2x160/4.5 \u03bcg twice daily"}, {"id": "OG002", "title": "Budesonide", "description": "Budesonide AC pMDI 2x160 \u03bcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "71"}, {"groupId": "OG002", "value": "71"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.04", "spread": "0.98"}, {"groupId": "OG001", "value": "1.92", "spread": "0.72"}, {"groupId": "OG002", "value": "2.12", "spread": "0.88"}]}]}, {"title": "Treatment Average (Trt Avg)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.68", "spread": "1.10"}, {"groupId": "OG001", "value": "1.45", "spread": "0.91"}, {"groupId": "OG002", "value": "2.02", "spread": "0.96"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparing mean changes from baseline to the average of the double-blind treatment period between Symbicort BA MDI 2x160/4.5 \u03bcg bid and Symbicort AC pMDI 2x160/4.5 \u00b5g bid.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "No adjustment were made for multiplicity for these supportive variables and nominal p-values were reported.", "pValue": "0.272", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model includes treatment and country as a factor and baseline value as covariate.", "paramType": "Mean Difference (Net)", "paramValue": "0.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.10", "ciUpperLimit": "0.35", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.11"}]}, {"type": "SECONDARY", "title": "Night-time Awakenings Due to Asthma Symptoms(% Awakening-free Nights)", "description": "The percentage of days with no awakenings due to asthma. Baseline= Mean % awakening-free nights during run-in period ; Trt Avg=Mean % awakening-free nights during double-blind period.", "populationDescription": "Full analysis set: It consist of all randomized patients who received at least one dose of study medication and contributed sufficient data for at least one efficacy endpoint (Primary variable).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of days with no awakenings", "timeFrame": "Recorded 6:00 - 11:00 AM for 14 weeks", "groups": [{"id": "OG000", "title": "Symbicort BA MDI", "description": "Symbicort BA MDI 2x160/4.5 \u03bcg twice daily"}, {"id": "OG001", "title": "Symbicort pMDI", "description": "Symbicort AC pDMI 2x160/4.5 \u03bcg twice daily"}, {"id": "OG002", "title": "Budesonide", "description": "Budesonide AC pMDI 2x160 \u03bcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "71"}, {"groupId": "OG002", "value": "71"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "78.54", "spread": "28.97"}, {"groupId": "OG001", "value": "78.76", "spread": "29.76"}, {"groupId": "OG002", "value": "81.59", "spread": "25.32"}]}]}, {"title": "Treatment Average (Trt Avg)", "categories": [{"measurements": [{"groupId": "OG000", "value": "83.73", "spread": "30.90"}, {"groupId": "OG001", "value": "89.93", "spread": "21.40"}, {"groupId": "OG002", "value": "84.62", "spread": "26.31"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparing mean changes from baseline to the average of the double-blind treatment period between Symbicort BA MDI 2x160/4.5 \u03bcg bid and Symbicort AC pMDI 2x160/4.5 \u00b5g bid.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "No adjustment were made for multiplicity for these supportive variables and nominal p-values were reported.", "pValue": "0.025", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model includes treatment and country as a factor and baseline value as covariate.", "paramType": "Mean Difference (Net)", "paramValue": "-6.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.41", "ciUpperLimit": "-0.79", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.69"}]}, {"type": "SECONDARY", "title": "Use of Rescue Medication Day and Night (Total Daily Rescue Medication Use)", "description": "Total daily rescue medication use is calculated as the sum of morning and evening use each day and averaged over the 12 weeks treatment periods to calculate the treatment period mean. Baseline= Mean rescue medication used during run-in period ; Trt Avg=Mean rescue medication used during double-blind period.", "populationDescription": "Full analysis set: It consist of all randomized patients who received at least one dose of study medication and contributed sufficient data for at least one efficacy endpoint (Primary variable).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Inhalations/24 hrs", "timeFrame": "Recorded between 6:00 - 11:00 AM from previous 12 hours and 6:00 -11:00 PM from previous 12 hours for 14 weeks", "groups": [{"id": "OG000", "title": "Symbicort BA MDI", "description": "Symbicort BA MDI 2x160/4.5 \u03bcg twice daily"}, {"id": "OG001", "title": "Symbicort pMDI", "description": "Symbicort AC pDMI 2x160/4.5 \u03bcg twice daily"}, {"id": "OG002", "title": "Budesonide", "description": "Budesonide AC pMDI 2x160 \u03bcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "71"}, {"groupId": "OG002", "value": "71"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.55", "spread": "2.48"}, {"groupId": "OG001", "value": "2.19", "spread": "1.75"}, {"groupId": "OG002", "value": "2.65", "spread": "2.36"}]}]}, {"title": "Treatment Average (Trt Avg)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.81", "spread": "2.67"}, {"groupId": "OG001", "value": "1.26", "spread": "1.60"}, {"groupId": "OG002", "value": "2.34", "spread": "2.38"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparing mean changes from baseline to the average of the double-blind treatment period between BAI Symbicort BA MDI 2x160/4.5 \u03bcg bid and pMDI Symbicort AC pMDI 2x160/4.5 \u00b5g bid.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "No adjustment were made for multiplicity for these supportive variables and nominal p-values were reported.", "pValue": "0.258", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model includes treatment and country as a factor and baseline value as covariate.", "paramType": "Mean Difference (Net)", "paramValue": "0.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.19", "ciUpperLimit": "0.71", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.23"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "'Number of participants in the safety analysis set is (71 for all the group)as 1 patients from the Budesonide group has not taken any dose of the IP, so not included in the Safety population'", "eventGroups": [{"id": "EG000", "title": "Budesonide", "seriousNumAffected": 0, "seriousNumAtRisk": 71, "otherNumAffected": 3, "otherNumAtRisk": 71}, {"id": "EG001", "title": "Symbicort BA MDI", "seriousNumAffected": 0, "seriousNumAtRisk": 71, "otherNumAffected": 2, "otherNumAtRisk": 71}, {"id": "EG002", "title": "Symbicort pMDI", "seriousNumAffected": 1, "seriousNumAtRisk": 71, "otherNumAffected": 7, "otherNumAtRisk": 71}], "seriousEvents": [{"term": "APPENDICITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}]}], "otherEvents": [{"term": "VIRAL UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 71}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 7, "numAffected": 7, "numAtRisk": 71}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "No. of participants in the safety analysis set is (71 for all the group) as 1 patients from the Budesonide group has not taken any dose of the IP, so not included in the Safety population."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than less than or equal to 180 days from the date of AZ's request to allow for the filing of a patent app or the taking of such measures as AZ deems appropriate to establish and preserve its proprietary rights in teh material being submitted."}, "pointOfContact": {"title": "Goran Eckerwall, MD", "organization": "Astrazeneca", "email": "aztrial_results_posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"browseLeaves": [{"id": "M4556", "name": "Asthma", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}, {"id": "D000069502", "term": "Budesonide, Formoterol Fumarate Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M304", "name": "Formoterol Fumarate", "relevance": "LOW"}, {"id": "M452", "name": "Budesonide, Formoterol Fumarate Drug Combination", "asFound": "Early Stage", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}